Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 19/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 8/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 8/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4737469 | 0.91 | MAPK1 (0.67) | MAPK1MAPK14PIK3CAMAPK8MAPK9 | |
| SCHEMBL12979746 | 0.90 | MAPK1 (0.59) | MAPK1MAPK14PIK3CAMAPK8MAPK9 | |
| SCHEMBL4738408 | 0.89 | MAPK1 (0.50) | MAPK1MAPK14PIK3CAMAPK8MAPK9 | |
| SCHEMBL4737212 | 0.89 | MAPK1 (0.61) | MAPK1MAPK14PIK3CAMAPK8MAPK9 | |
| SCHEMBL4739232 | 0.87 | MAPK1 (0.52) | MAPK1MAPK14PIK3CAMAPK8MAPK9 | |
| SCHEMBL5445419 | 0.87 | MAPK1 (0.77) | MAPK1MAPK14PIK3CAMAPK8MAPK9 | |
| SCHEMBL4679703 | 0.86 | MAPK1 (0.52) | MAPK1MAPK14PIK3CAMAPK8MAPK9 | |
| SCHEMBL12979362 | 0.86 | MAPK1 (0.48) | MAPK1MAPK14PIK3CAMAPK8MAPK9 | |
| SCHEMBL12979427 | 0.86 | MAPK1 (0.53) | MAPK1MAPK14PIK3CAMAPK8MAPK9 | |
| SCHEMBL12979378 | 0.86 | MAPK1 (0.48) | MAPK1MAPK14PIK3CAMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1962854-B1 | PYRIDOPYRAZINE DERIVATIVES AND USE THEREOF AS MODULATORS OF THE SIGNAL TRANSDUCTION PATHS | TERNA ZENTARIS GMBH (DE) | 2015-05-06 | — | — | EP | claimed |
| EP-1636228-B1 | NOVEL PYRIDOPYRAZINES AND USE THEREOF AS KINASE MODULATORS | AETERNA ZENTARIS GMBH (DE) | 2008-10-22 | — | — | EP | claimed |
| US-8937068-B2 | Pyridopyrazine derivatives and their use | ZENTARIS GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ZENTARIS GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | PLPBP, PDXK, MAP4K2 | MAPK1 58/4885MAPK14 99/4885PIK3CA 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.